Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 20/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 16/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17539231 | 1.00 | HCRTR2 (0.53) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL17495615 | 1.00 | HCRTR2 (0.53) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL17495614 | 1.00 | HCRTR2 (0.53) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL2904344 | 0.84 | HCRTR2 (0.58) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL17830177 | 0.84 | HCRTR2 (0.58) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL903254 | 0.84 | HCRTR2 (0.58) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL8217802 | 0.84 | HCRTR2 (0.58) | HCRTR2HCRTR1CYP3A4 | |
| Bromide SCHEMBL19894024 | 0.82 | HCRTR2 (0.52) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL17502930 | 0.80 | HCRTR2 (0.52) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL8056064 | 0.79 | HCRTR1 (0.62) | HCRTR2HCRTR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | SANDOZ AG (CH) | 2018-07-24 | — | — | US | disclosed |
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | SANDOZ AG (CH) | 2017-08-03 | — | — | US | disclosed |
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | SANDOZ AG (CH) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217947-A1 | Novel Route of Synthesis for the Preparation of Suvorexant | CYP51A1, CYP3A5, HCRTR2 | HCRTR2 3/4885HCRTR1 5/4885CYP3A4 6/4885 |
| US-10030010-B2 | Route of synthesis for the preparation of suvorexant | CYP51A1, CYP3A5, HCRTR2 | HCRTR2 3/4885HCRTR1 15/4885CYP3A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.